Japan· JP-1179005F2025
ヒドロキシジン塩酸塩
A hydroxyzine product containing ヒドロキシジン塩酸塩, registered in Japan by ファイザー, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Hydroxyzine is registered in 15 of 19 countries.
Countries holding a registration under ATC N05BB01 (hydroxyzine), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 8 of them publish a price we can compare per daily dose
Hydroxyzine · ATC N05BB01
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of hydroxyzine costs, country by country.
Normalised to the WHO defined daily dose (75 mg), the median price runs from $0.16 in United States to $1.68 in Switzerland — a ×11 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Hydroxyzine · price per daily dose (75 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1.68
- US United States$0.16 (acquisition cost)
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ヒドロキシジン塩酸塩
- Manufacturer
- ファイザー
- Country
- Japan (JP)
- ATC code
- N05BB01
- ATC class
- Hydroxyzine
- Defined daily dose
- 75 mg, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
410 interactions on record for hydroxyzine.
Graded by severity as the source publishes them — 46 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Hydroxyzine · interactions on record
410 records
- 46 severe
- 199 moderate
- 5 minor
- 160 info
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- Potassium chlorideA12BA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N05BB01
Hydroxyzine, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bfa3763f-215f-40ce-bd97-990e027175aa GET /v1/drugs/bfa3763f-215f-40ce-bd97-990e027175aa?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "２５ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "1179005F2025",
"category": "内用薬",
"price_yen": 6.3,
"generic_name": "ヒドロキシジン塩酸塩",
"product_name_jp": null,
"therapeutic_class": "1179",
"transitional_expiry": null
}See everything about hydroxyzine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.